Ligand Pharmaceuticals (LGND) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to -$664.5 million.
- Ligand Pharmaceuticals' Enterprise Value fell 20254.64% to -$664.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$664.5 million, marking a year-over-year decrease of 20254.64%. This contributed to the annual value of -$256.2 million for FY2024, which is 5041.19% down from last year.
- According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Enterprise Value is -$664.5 million, which was down 20254.64% from -$245.0 million recorded in Q2 2025.
- Over the past 5 years, Ligand Pharmaceuticals' Enterprise Value peaked at -$121.4 million during Q3 2022, and registered a low of -$664.5 million during Q3 2025.
- In the last 5 years, Ligand Pharmaceuticals' Enterprise Value had a median value of -$226.9 million in 2024 and averaged -$262.4 million.
- As far as peak fluctuations go, Ligand Pharmaceuticals' Enterprise Value soared by 6273.09% in 2021, and later plummeted by 20254.64% in 2025.
- Ligand Pharmaceuticals' Enterprise Value (Quarter) stood at -$341.1 million in 2021, then surged by 37.89% to -$211.9 million in 2022, then increased by 19.62% to -$170.3 million in 2023, then plummeted by 50.41% to -$256.2 million in 2024, then plummeted by 159.41% to -$664.5 million in 2025.
- Its Enterprise Value stands at -$664.5 million for Q3 2025, versus -$245.0 million for Q2 2025 and -$208.9 million for Q1 2025.